Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
casusanima schreef op 12 juli 2019 14:47 :
? Waarom zou u niet kunnen short gaan in een aandeel ? U werkt bij Biocartis (of een stakeholder) ?
[...]
Probeer het maar eens en vertel me dan of het gelukt is.
I never heard back from anyone as to what Biocartis was going to do with the $125 million Euro proceeds from the early May convertible offering. The press release was not very specific and pretty much covered all of their operations, so I'll launch my hypothesis. My guess is that Biocartis has ponied up for their half of a cartridge manufacturing plant in SE China. With the US trade sanctions against China, they are looking for ways to keep the growth engine humming. This dropped into their lap as a shovel ready project at a very opportune time. They can make a deal with an emerging EU company and respond to a growing need for cancer diagnostic products. China has fast increasing lung and breast cancer rates. A cost effective IVD product to assist in CDx prescriptions appears much more beneficial than building any more ghost cities! I expect a big announcement at a point in time when China can use it to their benefit to show that business is proceeding just fine despite the US tariffs and to demonstrate that the US is in effect locking their companies out of the fastest growing market in the world. This is just a hunch, but it explains why BCART needed to raise so much in funding in May on top of the $E 55M raised in January. Any Thoughts? FL
Flatlander schreef op 15 juli 2019 22:55 :
I never heard back from anyone as to what Biocartis was going to do with the $125 million Euro proceeds from the early May convertible offering. The press release was not very specific and pretty much covered all of their operations, so I'll launch my hypothesis. My guess is that Biocartis has ponied up for their half of a cartridge manufacturing plant in SE China. With the US trade sanctions against China, they are looking for ways to keep the growth engine humming. This dropped into their lap as a shovel ready project at a very opportune time. They can make a deal with an emerging EU company and respond to a growing need for cancer diagnostic products. China has fast increasing lung and breast cancer rates. A cost effective IVD product to assist in CDx prescriptions appears much more beneficial than building any more ghost cities! I expect a big announcement at a point in time when China can use it to their benefit to show that business is proceeding just fine despite the US tariffs and to demonstrate that the US is in effect locking their companies out of the fastest growing market in the world.
This is just a hunch, but it explains why BCART needed to raise so much in funding in May on top of the $E 55M raised in January.
Any Thoughts?
FL
Je denkt toch hopelijk niet dat Biocartis geld gaat verdienen in China....???
Are you suggesting that all companies that market products in China are doing it for reasons other than a profit incentive? Apple is citing the China tariff problem as a major reason why they will miss estimates. I see the IVD market opportunities being a good fit in China. 1.4 billion people and an aging populace with an increasing cancer rate. Widely dispersed hospitals and clinics that could benefit from a fast TAT molecular pathway diagnosis. My only concerns are whether the Chinese will respect the intellectual property. Given the current focus on this issue, I don't think they would risk alienating the EU trading partner given the current state of the US relationships. FLwww.youtube.com/watch?v=hKfsueeSy_w
Flatlander schreef op 16 juli 2019 17:01 :
Are you suggesting that all companies that market products in China are doing it for reasons other than a profit incentive? Apple is citing the China tariff problem as a major reason why they will miss estimates.
I see the IVD market opportunities being a good fit in China. 1.4 billion people and an aging populace with an increasing cancer rate. Widely dispersed hospitals and clinics that could benefit from a fast TAT molecular pathway diagnosis. My only concerns are whether the Chinese will respect the intellectual property. Given the current focus on this issue, I don't think they would risk alienating the EU trading partner given the current state of the US relationships.
www.youtube.com/watch?v=hKfsueeSy_w Chinese patiënten mogen niks kosten. Ik ken ook geen enkele grote farmaceut die geld verdient in China.
DeZwarteRidder schreef op 16 juli 2019 17:28 :
[...]
Chinese patiënten mogen niks kosten.
Ik ken ook geen enkele grote farmaceut die geld verdient in China.
don’t mind ‘De Zwarte Ridder’; he has never anything useful to say, in fact just think of the opposite and then you may take his ‘advice’. I know the company Biocartic quite well and believe me that they are investing their money very wisely, I am a LT investor and support the average price target of approx € 18. This may very well going to happen within a few months or at least before the end of this year!
Bio-belegger I really don't mind opposing opinions as long as they are supported with good logic. In order to survive shorts often have to have done extensive research. Biocartis' chart is boring and suggests further near term weakness. That said, I cannot find any investments in the U.S. with as many positive catalysts. So I definitely can make a case for it doubling overnight. Ok maybe over a month. The recent convertible cash raise on top of the January equity offering seems to suggest a urgent opportunity that was not apparent a few months earlier. Hopefully we get more color on that during the September conf call With the Gilead Galapagos news it appears that companies founded by Rudi Pauwels have a good track record of succeeding. Hopefully, Biocartis is next! FL
Bio-belegger schreef op 16 juli 2019 19:28 :
[...] don’t mind ‘De Zwarte Ridder’; he has never anything useful to say, in fact just think of the opposite and then you may take his ‘advice’. I know the company Biocartic quite well and believe me that they are investing their money very wisely, I am a LT investor and support the average price target of approx € 18. This may very well going to happen within a few months or at least before the end of this year!
Oooja, vertel eens waar Biocartis die 125 miljoen voor gaat gebruiken; voor bonussen...??? Biocartis zal nog minstens 5 jaar lang verliezen lijden.
GHDX receives upgrade on Reimbursement in Germany.www.genomeweb.com/business-news/genom... www.prnewswire.com/news-releases/geno... I keep saying that I like BCART as a better way to play this news. Assuming validation goes well The Oncotype Dx Breast test should launch in 2020! I think they are citing 40,000 tests per year and 120-160$M. Besides the milestone payments Biocartis will receive an undisclosed royalty on the cartriges. They will also see the ramp in additional placement of consoles, which I don't believe they split with GHDX. My guess is that the royalty should provide an ongoing $8-$15M/year in Onco Dx cartridge sales in Germany. They look to be the first in the EU with France and Spain to follow. FL
Sysmex still pounding the MAF >1% sensitivity results. www.prnewswire.com/news-releases/liqu...
I'm not huge into technical analysis. But the link you posted confirms my short term negative belief. I think BCART could revisit the 10.0 area. However, I can also come up with a scenario where it goes up 40 or 50% in a day. Presently news is getting discounted until it shows up in the financials. I think we are a year away from starting to see a lot of traction in the financials. FL
Exact Sciences in advanced talks to purchase GHDX. Don't think it would affect the relationship with Biocartis.finance.yahoo.com/news/exact-sciences...
Mooi volume vandaag. Bijna driemaal zoveel als het gemiddelde. En een aangename koersstijging. Hopelijk gebaseerd op iets fundamenteel waardoor de stijgende trend kan verder gezet worden.
For a fistful of dollars schreef op 31 juli 2019 16:31 :
Mooi volume vandaag. Bijna driemaal zoveel als het gemiddelde. En een aangename koersstijging. Hopelijk gebaseerd op iets fundamenteel waardoor de stijgende trend kan verder gezet worden.
In ieder geval weinig nieuws over gevonden, zoals gewoonlijk altijd een communicatieprobleem bij Biocartis.
Conroy the CEO of Exact Sciences (EXAS) indicated on Bloomberg that they were largely acquiring GHDX because it strengthened their position to roll out their product Cologard and OncoDx throughout the world. A large part of GHDX strategy for worldwide roll-out is thru Idylla! The market is starting to put 2+2 together to see that BCART is an integral team member for this roll-out. It will likely be the Sept 4 call before we get details from BCART so their is time to add shares. I'm looking for more color on BCARTs roll in the combination. Also, looking for info on the China relationship. FL
DeZwarteRidder schreef op 17 juli 2019 10:20 :
[...]
Oooja, vertel eens waar Biocartis die 125 miljoen voor gaat gebruiken; voor bonussen...???
Biocartis zal nog minstens 5 jaar lang verliezen lijden.
ken de gij geen engels ? das triest !
PERSBERICHT 5 augustus 2019, 07:00 CEST (4 augustus 2019, 22:00 PDT) Studie met performantiedata over Idylla (TM) NRAS-BRAF Mutatie Test op 71e AACC Annual Scientific Meeting in Anaheim, CA (VS) Mechelen, België, 5 augustus 2019 -- Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussel: BCART), kondigt vandaag aan dat een studie poster(1) over de performantie van de Idylla(TM) NRAS-BRAF Mutatie Test (RUO(2) ) zal worden gepresenteerd door Dr. Gregory Tsongalis, PhD (directeur van het Laboratorium voor Klinische Genomica en Geavanceerde Technologie van Dartmouth-Hitchcock Medical Center) op de 71e AACC ('American Association for Clinical Chemistry') Annual Scientific Meeting die plaatsvindt tussen 4-8 augustus in Anaheim, CA (VS). De studie concludeert dat het Idylla(TM) systeem het mogelijk maakt om snel en nauwkeurig NRAS- en BRAF-mutaties in melanoom te testen, rechtstreeks vanop FFPE(3) weefsel, en dat de eenvoud en gebruiksgemak in vergelijking met andere beschikbare moleculaire technieken Idylla(TM) geschikt maakt voor kleine centra die hiervoor geen specifiek opgeleid personeel en infrastructuur hebben. Verder concludeert de studie dat het Idylla(TM) systeem ook complementair kan zijn met NGS (Next-Generation Sequencing) door zijn veel snellere doorlooptijden. In de studie werden tweeëntwintig gearchiveerde FFPE-melanoom weefselstalen getest op het Idylla(TM) systeem met behulp van de Idylla(TM) NRAS-BRAF Mutatie Test (RUO). Van deze stalen hadden acht een mutatie in BRAF, zes hadden een mutatie in NRAS en acht hadden geen mutaties in BRAF of NRAS zoals bepaald door eerdere NGS testing. Het Idylla(TM) systeem detecteerde met succes mutaties in BRAF en NRAS en de resultaten waren volledig in overeenstemming met resultaten die eerder via NGS(4) verkregen werden. Idylla(TM) produceerde de resultaten snel met een doorlooptijd van ongeveer twee uur. Dr. Gregory Tsongalis, PhD, directeur van het Laboratorium voor Klinische Genomica en Geavanceerde Technologie van Dartmouth-Hitchcock Medical Center, licht toe: "Het Idylla(TM) systeem kan potentieel een belangrijke rol spelen in snelle screening op actiegerichte mutaties voorafgaand aan NGS analyse, ook voor kleine laboratoriumcentra die geen moleculaire diagnostiek infrastructuur of getraind personeel hebben." De poster zal op 7 augustus 2019 worden gepresenteerd door Dr. Gregory Tsongalis, PhD, directeur van het Laboratorium voor Klinische Genomica en Geavanceerde Technologie van Dartmouth-Hitchcock Medical Center op de 71e AACC Annual Scientific Meeting in Anaheim, CA (VS). --- EINDE ---
MoreandMore Thanks for posting the Biocartis presentation from AACC. The statement that follows: ""The Idylla (TM) system can potentially play an important role in rapid screening for action-oriented mutations prior to NGS analysis, also for small laboratory centers that do not have molecular diagnostics infrastructure or trained have staff. " makes me certain that much of BCARTs natural market is probably smaller hospitals, clinics,etc. They do not have the same access to NGS. For this reason prioritizing the FDA approval is a paramount goal. Getting this authorization will open the door for these smaller facilities to recover the cost of running the assay. Because the BRAC and NRAS assay costs are based on the characterization and not where it is conducted or how economically it is conducted, Idylla will be a profitable platform for the user and this will accelerate its adoption. The user will be able to bill it out at much higher rates then the cost of a cartridge. BCART has partners with considerable expertise in winning FDA approvals. They have a lot of money to throw at winning the approvals. This effort should be greatly accelerated. I look forward to the midyear update in a month. FL
Een goed produkt is één zaak... Je moet het nog verkopen... Zie Thrombo en mdxh...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee